Convergent Therapeutics
Radiopharmaceutical company developing targeted alpha therapy (TAT) for prostate cancer using PSMA-targeted actinium-225 conjugates.
Location
New York, New York, USA
Founded
2021
Investors
1
Categories
therapeutics, biotech, oncology, radiopharmaceuticals, prostate-cancer
Notes
Convergent Therapeutics is a radiopharmaceutical company focused on developing targeted alpha therapy (TAT) for the treatment of prostate cancer. The company's lead program CONV01-α is a PSMA-targeted actinium-225 radioligand therapy designed to deliver highly potent alpha radiation directly to cancer cells.
Backed by Novo Holdings, Convergent is advancing next-generation radiopharmaceuticals that leverage the precision of targeted alpha therapy to treat aggressive cancers with improved efficacy and safety profiles.
Team
- Philip Kantoff, M.D. - Executive Chairman
- Former Chief of Genitourinary Medical Oncology at Dana-Farber Cancer Institute
- Vincent O'Neill, M.D. - Chief Executive Officer
- LinkedIn: linkedin.com/in/vincentoneill
Additional Research Findings
- Backed by Novo Holdings
- Targeted alpha therapy (TAT) platform
- CONV01-α: PSMA-targeted actinium-225 therapy
- Focus on prostate cancer treatment
- Radiopharmaceutical approach to oncology
- New York headquarters
- Next-generation radioligand therapy
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Novo Holdings | Hellerup, Denmark | biotech-focused | seedseries-a+3 | 13 |